Literature DB >> 10578128

Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.

J F Desaphy1, D Conte Camerino, C Franchini, G Lentini, V Tortorella, A De Luca.   

Abstract

1 The antiarrhythmic drug mexiletine (Mex) is also used against myotonia. Searching for a more efficient drug, a new compound (Me5) was synthesized substituting the methyl group on the chiral carbon atom of Mex by an isopropyl group. Effects of Me5 on Na+ channels were compared to those of Mex in rat skeletal muscle fibres using the cell-attached patch clamp method. 2 Me5 (10 microM) reduced the maximal sodium current (INa) by 29.7+/-4.4 % (n=6) at a frequency of stimulation of 0.3 Hz and 65.7+/-4.4 % (n=6) at 1 Hz. At same concentration (10 microM), Mex was incapable of producing any effect (n=3). Me5 also shifted the steady-state inactivation curves by -7. 9+/-0.9 mV (n=6) at 0.3 Hz and -12.2+/-1.0 mV (n=6) at 1 Hz. 3 In the presence of sea anemone toxin II (ATX; 5 microM), INa decayed more slowly and no longer to zero, providing a model of sodium channel myotonia. The effects of Me5 on peak INa were similar whatever ATX was present or not. Interestingly, Me5 did not modify the INa decay time constant nor the steady-state INa to peak INa ratio. 4 Analysis of ATX-induced late Na+ channel activity shows that Me5 did not affect mean open times and single-channel conductance, thus excluding open channel block property. 5 These results indicate that increasing hindrance on the chiral atom of Mex increases drug potency on wild-type and ATX-induced noninactivating INa and that Me5 might improve the prophylaxis of myotonia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10578128      PMCID: PMC1571747          DOI: 10.1038/sj.bjp.0702901

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.

Authors:  W Shimizu; C Antzelevitch
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

2.  Sodium channel selectivity filter regulates antiarrhythmic drug binding.

Authors:  A Sunami; S C Dudley; H A Fozzard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

3.  A common local anesthetic receptor for benzocaine and etidocaine in voltage-gated mu1 Na+ channels.

Authors:  G K Wang; C Quan; S Wang
Journal:  Pflugers Arch       Date:  1998-01       Impact factor: 3.657

4.  Mechanism of lidocaine block of late current in long Q-T mutant Na+ channels.

Authors:  R Dumaine; G E Kirsch
Journal:  Am J Physiol       Date:  1998-02

Review 5.  From mutation to myotonia in sodium channel disorders.

Authors:  S C Cannon
Journal:  Neuromuscul Disord       Date:  1997-06       Impact factor: 4.296

6.  Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide.

Authors:  A De Luca; F Natuzzi; G Falcone; A Duranti; G Lentini; C Franchini; V Tortorella; D C Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-12       Impact factor: 3.000

7.  Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.

Authors:  S Sicouri; D Antzelevitch; C Heilmann; C Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  1997-11

8.  Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel alpha subunit.

Authors:  J C Rogers; Y Qu; T N Tanada; T Scheuer; W A Catterall
Journal:  J Biol Chem       Date:  1996-07-05       Impact factor: 5.157

9.  Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse.

Authors:  A De Luca; S Pierno; F Natuzzi; C Franchini; A Duranti; G Lentini; V Tortorella; H Jockusch; D C Camerino
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

10.  Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.

Authors:  S G Priori; C Napolitano; F Cantù; A M Brown; P J Schwartz
Journal:  Circ Res       Date:  1996-06       Impact factor: 17.367

View more
  5 in total

1.  Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.

Authors:  S Talon; A De Luca; M De Bellis; J F Desaphy; G Lentini; A Scilimati; F Corbo; C Franchini; P Tortorella; H Jockusch; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Neuroprotective effect of mexiletine in the central nervous system of diabetic rats.

Authors:  Ozkan Ates; Suleyman R Cayli; Eyup Altinoz; Neslihan Yucel; Ayhan Kocak; Ozcan Tarim; Akif Durak; Yusuf Turkoz; Saim Yologlu
Journal:  Mol Cell Biochem       Date:  2006-03-16       Impact factor: 3.396

3.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

4.  Molecular Insights into the Local Anesthetic Receptor within Voltage-Gated Sodium Channels Using Hydroxylated Analogs of Mexiletine.

Authors:  Jean-François Desaphy; Antonella Dipalma; Teresa Costanza; Roberta Carbonara; Maria Maddalena Dinardo; Alessia Catalano; Alessia Carocci; Giovanni Lentini; Carlo Franchini; Diana Conte Camerino
Journal:  Front Pharmacol       Date:  2012-02-15       Impact factor: 5.810

Review 5.  Ion channel pharmacology.

Authors:  Diana Conte Camerino; Domenico Tricarico; Jean-François Desaphy
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.